U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27FN4O2
Molecular Weight 410.4854
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE

SMILES

Cc1c(CCN2CCC(CC2)c3c4ccc(cc4on3)F)c(=O)n5CCCCc5n1

InChI

InChIKey=RAPZEAPATHNIPO-UHFFFAOYSA-N
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C23H27FN4O2
Molecular Weight 410.4854
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/risperidone.html http://www.wikidoc.org/index.php/Risperidone_(oral) http://www.rxlist.com/risperdal-drug.htm

Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is FDA approved for the treatment of schizophrenia, bipolar mania, irritability associated with autistic disorder. Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Vice versa, Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Common adverse reactions include increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia , metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, potential for cognitive and motor impairment, seizures, dysphagia, priapism, disruption of body temperature regulation.

Originator

Curator's Comment:: # Janssen Pharmaceutica N.V.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Primary
RISPERDAL

Approved Use

INDICATIONS & USAGE Risperidone tablets are indicated for the acute and maintenance treatment of schizophrenia [see Clinical Studies (14.1)

Launch Date

7.5712319E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.77 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
83.1 ng × h/mL
2 mg 2 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
53.86 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.88 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RISPERIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Disc. AE: Dizziness, Agitation...
AEs leading to
discontinuation/dose reduction:
Dizziness (1%)
Agitation (1%)
Somnolence (0.5%)
Hypotension postural (0.5%)
Tachycardia (0.5%)
Akathisia (1%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Disc. AE: Parkinsonism, Somnolence...
AEs leading to
discontinuation/dose reduction:
Parkinsonism (0.4%)
Somnolence (0.2%)
Dizziness (0.2%)
Dystonia (0.2%)
SGOT increased (0.2%)
SGPT increased (0.2%)
Sources:
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Disc. AE: Dizziness, Nausea...
AEs leading to
discontinuation/dose reduction:
Dizziness (1.4%)
Nausea (1.4%)
Agitation (1.1%)
Parkinsonism (0.8%)
Somnolence (0.8%)
Dystonia (0.5%)
Abdominal pain (0.5%)
Hypotension postural (0.3%)
Tachycardia (0.3%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Disc. AE: Somnolence, Dizziness...
AEs leading to
discontinuation/dose reduction:
Somnolence (2%)
Dizziness (2%)
Anorexia (1%)
Anxiety (1%)
Ataxia (1%)
Hypotension (1%)
Palpitation (1%)
Sources:
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Disc. AE: Somnolence, Nausea...
AEs leading to
discontinuation/dose reduction:
Somnolence (5%)
Nausea (3%)
Abdominal pain (2%)
Vomiting (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypotension postural 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Somnolence 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Tachycardia 0.5%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Agitation 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Akathisia 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Dizziness 1%
Disc. AE
16 mg 1 times / day multiple, oral (max)
Recommended
Dose: 16 mg, 1 times / day
Route: oral
Route: multiple
Dose: 16 mg, 1 times / day
Sources:
unhealthy, adult
n = 198
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 198
Sources:
Dizziness 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Dystonia 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
SGOT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
SGPT increased 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Somnolence 0.2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Parkinsonism 0.4%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, adult
n = 448
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: adult
Population Size: 448
Sources:
Hypotension postural 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Tachycardia 0.3%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Abdominal pain 0.5%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Dystonia 0.5%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Parkinsonism 0.8%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Somnolence 0.8%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Agitation 1.1%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Dizziness 1.4%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Nausea 1.4%
Disc. AE
8 mg 1 times / day multiple, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 366
Health Status: unhealthy
Condition: Schizophrenia
Age Group: adult
Population Size: 366
Sources:
Anorexia 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Anxiety 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Ataxia 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Hypotension 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Palpitation 1%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Dizziness 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Somnolence 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 106
Health Status: unhealthy
Condition: Schizophrenia
Age Group: child
Population Size: 106
Sources:
Abdominal pain 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Vomiting 2%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Nausea 3%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Somnolence 5%
Disc. AE
6 mg 1 times / day multiple, oral (max)
Recommended
Dose: 6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 6 mg, 1 times / day
Sources:
unhealthy, child
n = 111
Health Status: unhealthy
Condition: Bipolar Mania
Age Group: child
Population Size: 111
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [IC50 38.1 uM]
weak
no (co-administration study)
Comment: RISPERDAL did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP2D6
Page: 37.0
yes [IC50 15.78 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Fluoxetine and paroxetine (CYP 2D6 inhibitors) have been shown to increase the plasma concentration of risperidone 2.5-2.8 fold and 3-9 fold, respectively
Page: 36.0
minor
minor
yes (co-administration study)
Comment: Carbamazepine co-administration with oral RISPERDAL decreased the steady-state plasma concentrations of risperidone by about 50%;
Page: 4.0
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
1999 Dec
Two cases of risperidone-induced tardive dyskinesia and a review of the literature.
1999 Jul
Risperidone-induced tardive dystonia and psychosis.
1999 Mar 20
Risperidone-induced absence of ejaculation.
1999 Sep
Risperidone in treatment-refractory schizophrenia.
1999 Sep
Case report of withdrawal syndrome after olanzapine discontinuation.
2000 Aug
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
2000 Dec 15
Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
2000 Feb
Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs.
2000 Jul
Acute confusional states during treatment with risperidone.
2000 Jun
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
2000 Jun
Relation between cholinesterase inhibitor and Pisa syndrome.
2000 Jun 24
Risperidone treatment of drug-related psychosis in patients with parkinsonism.
2000 Mar
Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
2000 Mar
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
2000 May
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
2000 May
[Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy].
2000 May
Lack of specific effects of selective D(1) and D(2) dopamine antagonists vs. risperidone on morphine-induced hyperactivity.
2000 May
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
2000 Nov
Risperidone-associated hyperprolactinemia.
2000 Nov-Dec
Risperidone and tardive dyskinesia: a case of blepharospasm.
2000 Oct
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
2000 Oct
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
2000 Sep
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
2000 Summer
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
2001
Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone.
2001 Apr
Risperidone-induced retrograde ejaculation.
2001 Apr
An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone.
2001 Apr
Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states.
2001 Apr
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
2001 Feb
Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone.
2001 Feb
Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).
2001 Feb
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
2001 Feb
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
2001 Feb
Drug induced akathisia, suicidal ideation and its treatment in the elderly.
2001 Feb
Combination risperidone and quetiapine therapy in refractory schizophrenia.
2001 Feb
A case of risperidone-induced stuttering.
2001 Feb
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
2001 Feb
Hyperthermia and chronic pancerebellar syndrome after cocaine abuse.
2001 Feb 26
Acute and long-term treatment of catatonia with risperidone.
2001 Jan
Does risperidone have a place in the treatment of nonschizophrenic patients?
2001 Jan
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
2001 Jan 1
Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.
2001 Jan 15
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.
2001 Jan 26
[Viewpoint of schizophrenic patients: a European survey].
2001 Jan-Feb
The evaluation of multiple surrogate endpoints.
2001 Mar
Fixed-dosed risperidone in mania: an open experimental trial.
2001 Mar
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
2001 Mar
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.
2001 Mar
Patents

Sample Use Guides

Initial dosing is generally 2 mg/day. Dose increases should then occur at intervals not less than 24 hours, in increments of 1–2 mg/day, as tolerated, to a recommended dose of 4–8 mg/day. Effective dose range - 0.5-16 mg (disease dependent).
Route of Administration: Other
Measurement of ATP contents in the neuronal cell line showed significantly increased levels after a 24-h treatment with 25 microg/mL risperidone.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:09 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:09 UTC 2021
Record UNII
L6UH7ZF8HC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
RISPERIDONE [EP MONOGRAPH]
Common Name English
R-64766
Code English
R 64 766
Code English
RISPERIDONE [WHO-DD]
Common Name English
RISPERIDONE [USAN]
Common Name English
RISPERIDONE [USP MONOGRAPH]
Common Name English
N05AX08
Code English
RISPERIDONE [ORANGE BOOK]
Common Name English
R-64,766
Code English
PERSERIS
Brand Name English
RISPERIDONE [HSDB]
Common Name English
RISPERIDONE [USP-RS]
Common Name English
RISPERIDONE [MART.]
Common Name English
RCN3028
Code English
RISPERDAL
Brand Name English
RCN-3028
Code English
RISPERIDONE [JAN]
Common Name English
R-64-766
Code English
NSC-759895
Code English
RISPERIDONE [EP]
Common Name English
LY-03004
Code English
RISPERIDONE [INN]
Common Name English
RISPERIDONE [USP]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-
Systematic Name English
RISPERIDONE [VANDF]
Common Name English
RISPERIDONE [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AX08
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
WHO-VATC QN05AX08
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
LIVERTOX 852
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
FDA ORPHAN DRUG 326110
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL85
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
LACTMED
Risperidone
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
EPA CompTox
106266-06-2
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
DRUG CENTRAL
2389
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
HSDB
7580
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
MERCK INDEX
M9631
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY Merck Index
PUBCHEM
5073
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
WIKIPEDIA
RISPERIDONE
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
MESH
D018967
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
INN
6085
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
EVMPD
SUB10335MIG
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
USP_CATALOG
1604654
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY USP-RS
CAS
106266-06-2
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
RXCUI
35636
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C29416
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
IUPHAR
96
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
DRUG BANK
DB00734
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
FDA UNII
L6UH7ZF8HC
Created by admin on Fri Jun 25 21:03:09 UTC 2021 , Edited by admin on Fri Jun 25 21:03:09 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
NON-INHIBITOR->OFF-TARGET
TARGET -> INHIBITOR
INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
NON-AGONIST->OFF-TARGET
Ki
INHIBITOR -> TARGET
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
BINDER->LIGAND
NON-INHIBITOR->OFF-TARGET
Ki
TARGET -> ACTIVATOR
INHIBITOR
Ki
TARGET -> INHIBITOR
INHIBITOR
Ki
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
INHIBITOR
Ki
NON-INHIBITOR->OFF-TARGET
Ki
NON-INHIBITOR->OFF-TARGET
TARGET -> INHIBITOR
INHIBITOR
Ki
TRANSPORTER -> SUBSTRATE
INHIBITOR
IC50
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE ACTIVE -> PARENT
in vitro mediators are CYP2D6 and CYP3A4
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP